Adult Clinical Trials - Non-immunologic

Clinical Research

ACTR-64 - Phase 2 study to evaluate the safety, pharmacokinetics and clinical activity of PI3K/mTOR inhibitor GDC-0084 in GBM patients with unmethylated O₆-methylguanine-methyltransferase (MGMT) promoter status

Poster Presenting Author(s)

• 

  Patrick Wen

  Director, Center For Neuro-Oncology
  Dana-Farber Cancer Institute

Author(s)

• JD

  John DeGroot

  University of Texas MD Anderson Cancer Center
• JB

  James Battiste

  Stephenson Cancer Center, University of Oklahoma Health Sciences Center
• SG

  Samuel Goldlust

  John Theurer Cancer Center
• JG

  James Garner

  Kazia Therapeutic Limited
• JS

  Jeremy Simpson

  Kazia Therapeutics Limited
• JK

  Jelle Kijlstra

  Covance Inc.
• AO

  Alan Olivero

  Genentech Inc
• 

  Timothy Cloughesy

  Professor
  University of California Los Angeles